The cerebrospinal fluid A‐T+ Alzheimer disease biomarker profile: prevalence and clinical relevance
Pontus Eriksson(Lund University), Henrik Zetterberg(University of Wisconsin–Madison), Joel Simrén(University of Gothenburg), Barbara B. Bendlin(University of Wisconsin–Madison), Kaj Blennow(Sahlgrenska University Hospital), Wagner S. Brum(Universidade Federal do Rio Grande do Sul), Erin M. Jonaitis(University of Wisconsin–Madison), Carol A. Van Hulle(University of Wisconsin–Madison), Ulf Andréasson(Sahlgrenska University Hospital), Gwendlyn Kollmorgen(Roche Pharma AG (Germany)), Sterling C. Johnson(Wisconsin Society for Cardiovascular and Pulmonary Health & Rehabilitation), Margherita Carboni(Roche (Switzerland)), Cynthia M. Carlsson(University of Wisconsin–Madison), Gilda E. Ennis(University of Wisconsin–Madison), Leslie M. Shaw(California University of Pennsylvania), Sanjay Asthana(University of Wisconsin–Madison), Nicholas J. Ashton(King's College London), Rebecca E. Langhough(University of Wisconsin–Madison), Tobey J. Betthauser(University of Wisconsin–Madison)
Cited by 2
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k